Filing identity and period
The supplied filing is FibroGen, Inc. (Nasdaq: FGEN), not Kyntra Bio, Inc.; the request metadata does not match the filing text. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2022. Amounts below are U.S. dollars.
Business context
FibroGen is a biopharmaceutical company developing pamrevlumab and roxadustat. Roxadustat is marketed for CKD-related anemia in China, Europe, Japan and other countries; pamrevlumab remains in clinical development. Roxadustat’s U.S. CKD-anemia application received an FDA complete response letter in 2021.
Financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $15.7 million | $156.0 million | $106.4 million | $218.8 million |
| Operating costs and expenses | $109.4 million | $105.0 million | $341.2 million | $372.1 million |
| Operating income (loss) | $(93.7) million | $51.0 million | $(234.9) million | $(153.3) million |
| Net income (loss) | $(91.7) million | $49.8 million | $(227.5) million | $(155.9) million |
| Net loss per share, diluted | $(0.98) | $0.54 | $(2.43) | $(1.69) |
| Cash used in operating activities | Not presented for quarter | Not presented for quarter | $93.4 million | $27.3 million |
At September 30, 2022, cash and cash equivalents were $156.0 million, investments were $270.3 million, and accounts receivable was $15.3 million—$441.6 million combined, down $148.8 million from year-end 2021. Working capital was approximately $222.2 million. Total liabilities were $562.6 million; the filing does not present conventional borrowings as a material balance, but reports $92.6 million in operating lease liabilities and $15.4 million in product development obligations. Nine-month operating cash outflow increased year over year. The company said available resources, including the expected $50 million NovaQuest financing, should fund operations for at least 12 months from the financial statements’ issuance date.
Gross or operating margins are not presented as key measures. The reported losses reflect substantial R&D spending; R&D was $235.2 million for the first nine months. The company reported an accumulated deficit of $1.49 billion.
Material changes versus comparable periods
- Q3 revenue fell 90%, largely because Q3 2021 included $120 million of EU regulatory milestones from Astellas and an $8 million Eluminex license payment. Nine-month revenue fell 51%; 2022 included a $25 million Russia approval milestone.
- China net product revenue rose 29% in Q3 and 41% year to date, to $17.4 million and $59.5 million, respectively. Management cited increased sales volume, partly offset by lower reimbursement pricing and unfavorable currency translation.
- Nine-month operating expenses declined 8%, including lower R&D and employee-related costs; Q3 expenses increased 4%, including higher pamrevlumab manufacturing development and legal costs.
- Cash used in operations was $93.4 million versus $27.3 million in the prior-year period. Cash, investments and receivables declined, with operating cash use and pipeline investment among the cited factors.
Outlook, commentary and risks
- Management expects continued losses and substantial funding needs. It said it has not agreed with AstraZeneca on further U.S. CKD-anemia development funding and does not expect to receive most or all remaining U.S./Rest-of-World milestones under that agreement.
- Clinical milestones then expected: MATTERHORN roxadustat MDS topline data in the first half of 2023; China chemotherapy-induced anemia data in mid-2023; pamrevlumab ZEPHYRUS-1 and LELANTOS-1 data in the first half of 2023; LELANTOS-2 data in the second half of 2023; ZEPHYRUS-2 data in mid-2024; and LAPIS pancreatic-cancer data in the first half of 2024.
- On November 4, 2022, after quarter-end, FibroGen agreed to receive $50 million from NovaQuest in exchange for a share of specified Astellas-territory roxadustat revenue, subject to repayment caps and other terms. This financing is not included in September 30 cash.
- Unusual revenue adjustments were significant: Q3 drug product revenue was negative $4.1 million, primarily from a $4.3 million estimate adjustment for Astellas Japan API shipments. Accrued API and bulk-product price true-ups totaled $66.5 million at quarter-end.
- Risks include clinical and regulatory uncertainty, the U.S. roxadustat CRL, reliance on Astellas and AstraZeneca, manufacturing and supply constraints, China-related operating and currency risks, and substantial cash burn. The filing also describes securities and derivative litigation, an SEC subpoena concerning roxadustat cardiovascular safety data, and challenges to certain roxadustat patents in China. Outcomes and potential losses were not estimable; no material legal accrual was recorded.
Most important facts to verify
- Confirm the intended issuer: the provided filing is FibroGen, Inc. (FGEN), not Kyntra Bio, Inc.
- Check the status and terms of the $50 million NovaQuest revenue-interest financing and its effect on future Astellas royalties and cash availability.
- Track operating cash burn, liquidity runway and the company’s stated 12-month funding assumption.
- Review the $66.5 million product-price true-up accrual and the assumptions behind variable consideration and deferred revenue.
- Monitor clinical readouts, FDA/regulatory developments, AstraZeneca collaboration funding or termination risk, and the pending litigation and SEC inquiry.